AXQ Capital LP Invests $996,000 in Becton, Dickinson and Company $BDX

Posted by Francis Steltz on Jun 3rd, 2026

AXQ Capital LP acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,133 shares of the medical instruments supplier’s stock, valued at approximately $996,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company during the third quarter worth about $25,000. Steph & Co. boosted its position in Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 65 shares during the last quarter. WPG Advisers LLC boosted its position in Becton, Dickinson and Company by 64.2% during the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 61 shares during the last quarter. Accredited Wealth Management LLC boosted its position in Becton, Dickinson and Company by 77.8% during the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 70 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in Becton, Dickinson and Company during the fourth quarter valued at approximately $32,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on BDX. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Stifel Nicolaus decreased their price objective on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Citigroup decreased their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. The Goldman Sachs Group reduced their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. Finally, Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a report on Tuesday, April 14th. Seven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and an average price target of $183.64.

Get Our Latest Stock Report on Becton, Dickinson and Company

Becton, Dickinson and Company Stock Down 0.9%

BDX stock opened at $144.07 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The stock’s 50 day simple moving average is $151.40 and its 200 day simple moving average is $176.68. The company has a market cap of $39.70 billion, a P/E ratio of 36.47, a price-to-earnings-growth ratio of 10.29 and a beta of 0.22. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.